Search results
David Fajgenbaum accounces the launch of Every Cure at the Clinton Global Initiative 2022https://everycure.org/
- 8 min
- 1064
- David Fajgenbaum
This month, we're thrilled to have Dr. David Fajgenbaum on our podcast. He is a clinician scientist, rare disease patient, author, and all-around incredible ...
- 42 min
- 2
- Canadian Rheumatology Association
LDA Research’s director Lucy Doorbar recently talked to Dr David Fajgenbaum about his journey to find a treatment for his rare Castleman disease, and how he ...
- 17 min
- 37
- Rare Together
Sep 24, 2024 · Now he’s on a mission to save thousands more. David Fajgenbaum, MD, MBA, nearly died from a rare disease. His own research — and dogged hope — unearthed a treatment. Now he’s using AI and groundbreaking research methods to help others. David Fajgenbaum, MD, MBA, with cofounders of Every Cure, which uses artificial intelligence to ...
- Stacy Weiner
Instead of helping people one at a time, Dr. David Fajgenbaum plans to match patients with existing drugs on a much larger scale. Every Cure Announces ARPA-H Funding at the White House Co-Founder Dr. David Fajgenbaum announces 3 year, 48.3M contract from ARPA-H at the Rare Disease Forum at the White House
David C. Fajgenbaum (born March 29, 1985) is an American immunologist and author who is currently an assistant professor at the Perelman School of Medicine of the University of Pennsylvania. [1] He is most well known for his research into Castleman disease .
People also ask
Who is Dr. David Fajgenbaum?
Where is Dr fajgenbaum now?
What is fajgenbaum's role in idiopathic Castleman disease?
What happened to fajgenbaum's mother?
David Fajgenbaum, MD, MBA, MSc, is a physician-scientist at the University of Pennsylvania and one of the youngest professors to receive tenure in the history of Penn Medicine, co-Founder & President of the Castleman Disease Collaborative Network, co-Founder & President of Every Cure, and the national bestselling author of ‘Chasing My Cure: A Doctor’s Race to Turn Hope Into Action.‘
